Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells-Reference-Cited by-同舟云学术

Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells

Published:2010-08-06 Issue:2 Volume:18 Page:271-281
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Kogan-Sakin I,Tabach Y,Buganim Y,Molchadsky A,Solomon H,Madar S,Kamer I,Stambolsky P,Shelly A,Goldfinger N,Valsesia-Wittmann S,Puisieux A,Zundelevich A,Gal-Yam E N,Avivi C,Barshack I,Brait M,Sidransky D,Domany E,Rotter V

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cdd201094.pdf

Reference28 articles.

1. Fridman JS, Lowe SW . Control of apoptosis by p53. Oncogene 2003; 22: 9030–9040.

2. Vousden KH . p53: death star. Cell 2000; 103: 691–694.

3. Bullock AN, Fersht AR . Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68–76.

4. Sigal A, Rotter V . Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788–6793.

5. Cadwell C, Zambetti GP . The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15–30.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors;OncoImmunology;2024-07-18

2. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer;Science Bulletin;2024-07

3. p53/MDM2 signaling pathway in aging, senescence and tumorigenesis;Seminars in Cancer Biology;2024-06

4. Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor;Cancers;2024-03-11

5. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy;Cancer Communications;2024-02-04